Disparities in access to sorafenib in communities with low socioeconomic status Journal Article

Authors: Sarpel, U.; Heskel, M.; Spivack, J. H.; Feferman, Y.; Ang, C.; Gany, F.
Article Title: Disparities in access to sorafenib in communities with low socioeconomic status
Abstract: Objective. In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment. Methods. The newly developed Case-Background method was used to estimate odds ratios for the impacts of various sociodemographic factors on sorafenib access in clinically eligible patients. Socioeconomic status was defined as a factor of median income and education level based on ZIP code of residence. Results. There was a strong association between sorafenib prescription and residence in an area of higher SES. While controlling for age, race/ethnicity, and insurance status, high SES residence doubled the odds of sorafenib prescription (OR=2.05, p<.01). Conclusions. Low socioeconomic status communities appear to have a reduced chance of receiving the only effective treatment for advanced HCC. © 2018, Johns Hopkins University Press. All rights reserved.
Keywords: hepatocellular carcinoma; sorafenib; socioeconomic status; health care disparities
Journal Title: Journal of Health Care for the Poor and Underserved
Volume: 29
Issue: 3
ISSN: 1049-2089
Publisher: Johns Hopkins University Press  
Date Published: 2018-08-01
Start Page: 1123
End Page: 1134
Language: English
DOI: 10.1353/hpu.2018.0083
PROVIDER: scopus
PUBMED: 30122687
PMCID: PMC7510390
Notes: J. Health Care Poor Underserved -- Export Date: 2 January 2019 -- Article -- CODEN: JHCUE -- Source: Scopus
Citation Impact
MSK Authors
  1. Francesca Mara Gany
    162 Gany